Novartis (SWX:NOVN) has recently attracted investor interest as its stock performance continues to trend upward over the past month. With steady momentum and consistent financials, many are watching to see if this trajectory will hold in the coming weeks.

See our latest analysis for Novartis.

With a strong start to the year, Novartis has seen its share price climb over 19% year-to-date, reflecting growing investor confidence and a string of positive financial updates. Momentum seems to be building, supported by a 1-year total shareholder return of 11% and impressive multi-year gains, reinforcing the view that Novartis may be regaining its stride.

If you’re keeping an eye on major healthcare movers, this is a perfect moment to explore more opportunities with our curated list: See the full list for free.

But with a share price hovering just above analyst targets and robust financials already factored in, the big question remains: is Novartis still undervalued, or has the market already priced in its next wave of growth?

Based on the most widely followed narrative, Novartis’s fair value estimate sits below the last closing price, suggesting analysts now see the company as slightly overvalued. This shift reflects rising expectations for growth but also higher future profit hurdles yet to be cleared.

Novartis' robust pipeline and rapid regulatory progress in advanced therapies (including biologics, gene, and cell therapies) positions the company to benefit from emerging healthcare technologies. This could potentially accelerate future earnings and margin growth as new high-value products launch. Expansion in emerging markets, particularly China (with Leqvio's strong out-of-pocket uptake and continued ex-U.S. growth in priority brands), increases Novartis' overall addressable market. This helps to mitigate saturation in developed geographies and drive future sales and cash flow.

Read the complete narrative.

The assumptions behind this fair value may raise eyebrows. Analysts are betting on powerful margin expansion and fresh product launches. Want the full story behind these bullish projections? Unpack the bold growth blueprint they are using to set their price target.

Result: Fair Value of $99.08 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, ongoing global pricing pressure and the looming threat of generic competition could quickly temper Novartis's current growth outlook.

Find out about the key risks to this Novartis narrative.

While analysts currently see Novartis as overvalued based on earnings growth, our DCF model presents a starkly different perspective. Using projected future cash flows, the SWS DCF analysis values the stock at CHF271.56, which suggests it could be trading at a steep discount. Which approach will ultimately prove more accurate as the story unfolds?

Look into how the SWS DCF model arrives at its fair value.

If you are curious about different outcomes or believe a deeper dive is needed, you can quickly craft your own Novartis narrative and test the numbers for yourself. Do it your way

A great starting point for your Novartis research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.

Want to stay ahead of the market? Venture beyond familiar names and boost your portfolio by tapping into powerful trends and tomorrow’s biggest winners, not just today’s headlines.

Uncover steady income potential and reliable earnings by starting your search with 3%;elm:context_link;itc:0;sec:content-canvas\\" class=\\"link \\">these 19 dividend stocks with yields > 3% offering competitive yields above 3%.

Target cutting-edge sectors with these 26 quantum computing stocks and get positioned early in companies at the forefront of quantum computing breakthroughs.

Make your next move with confidence by spotting bargains among these 888 undervalued stocks based on cash flows fueled by robust cash flows and untapped upside.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NOVN.swx.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com